|MDACC Study No:||2010-0374 (clinicaltrials.gov NCT No: NCT01202877)|
|Title:||A Combination of PKC412 and 5-azacytidine for the Treatment of Patients with Refractory, Relapsed or Untreated Acute Leukemia and Myelodysplastic Syndrome (MDS)|
|Principal Investigator:||Jorge Cortes|
|Treatment Agent:||5-Azacytidine; PKC412|
|Study Description:||The goal of this clinical research study is to learn if the combination of |
PKC412 (also called Midostaurin) and 5-azacytidine can help to control
refractory or relapsed acute leukemia and MDS. The safety and best dose of the
combination of the drugs will also be studied.